Doctors Note Logo

Published on: 9/26/2026

What are the worst side effects of Jardiance?

The most serious risks linked to Jardiance (empagliflozin) include diabetic ketoacidosis that can occur even with normal blood sugar, severe urinary tract infections that progress to kidney infection or sepsis, and a rare but life threatening genital infection called Fournier's gangrene (necrotizing fasciitis of the perineum). Other significant concerns involve dehydration and low blood pressure with fainting, acute kidney injury, severe allergic reactions, and dangerously low blood sugar when combined with insulin or sulfonylureas, while genital yeast infections are far more common but usually less dangerous. Warning signs such as fever, pain or swelling in the genital area, fruity smelling breath, nausea with vomiting, or reduced urination need urgent medical attention, and several factors including kidney function, hydration, and other medications change your personal risk, so see below to understand more.

Because these symptoms can overlap with ordinary illness, it helps to sort out whether what you are feeling is a mild reaction or an emergency before you decide how quickly to act. A free, instant, online symptom check can help you organize your symptoms, see possible explanations, and understand whether to call your prescriber now or seek immediate care.

Last reviewed for medical accuracy: 09/26/2026

answer background

Explanation

Worst Side Effects of Jardiance

Jardiance (empagliflozin) is an SGLT2 inhibitor prescribed for adults with type 2 diabetes. By helping the kidneys remove excess glucose in urine, it can improve blood sugar control and reduce the risk of cardiovascular complications. Like all medications, Jardiance carries a range of side effects—from mild to potentially life-threatening. Below is an evidence-based overview of the worst side effects of Jardiance, what to watch for, and when to seek medical attention.

Common vs. Serious Side Effects

Most people tolerate Jardiance well, but a small subset may experience severe reactions. Understanding which side effects are relatively benign and which demand urgent care can help you stay safe.

• Common (usually mild to moderate):
– Genital yeast infections
– Urinary tract infections
– Increased urination, thirst
– Nausea, constipation

• Potentially serious (rare but significant):
– Diabetic ketoacidosis (DKA)
– Serious urinary tract infections (UTIs)
– Acute kidney injury
– Hypotension (low blood pressure) and dehydration
– Fournier’s gangrene
– Bone fractures, amputation risk
– Hypoglycemia (when combined with insulin or secretagogues)
– Severe skin reactions

Below, we delve into the most alarming risks.


1. Diabetic Ketoacidosis (DKA)

Even with relatively normal blood sugars, Jardiance can trigger DKA—an accumulation of ketones leading to a dangerous acid–base imbalance.

Key points:

  • Onset may be subtle: nausea, abdominal pain, fatigue, rapid breathing.
  • Blood sugar levels can be only mildly elevated (<250 mg/dL).
  • Untreated DKA can progress to coma or death.

What to do:

  • If you experience persistent nausea, vomiting, or difficulty breathing, seek emergency care.
  • Do not stop or adjust your dose without contacting your healthcare provider.

2. Serious Urinary Tract Infections

While UTIs are common, Jardiance’s mechanism (increased glucose in urine) can raise the risk of:

  • Pyelonephritis (kidney infection)
  • Urosepsis (life-threatening bloodstream infection)

Warning signs:

  • Fever, chills
  • Back or flank pain
  • Burning with urination, urgency

Immediate action:

  • Seek prompt medical evaluation if you develop systemic symptoms (fever, malaise) alongside urinary issues.

3. Acute Kidney Injury

Jardiance may reduce blood flow to the kidneys, potentially leading to acute kidney injury (AKI), especially in:

  • Dehydrated patients
  • Those on diuretics or NSAIDs
  • Individuals with preexisting kidney disease

Symptoms:

  • Sudden decrease in urine output
  • Swelling in legs, ankles
  • Confusion, weakness

Prevention and monitoring:

  • Stay well-hydrated, especially during illness or hot weather.
  • Have periodic kidney function tests (serum creatinine, eGFR).

4. Hypotension and Volume Depletion

By promoting glucose—and with it, water—loss, Jardiance can cause low blood pressure or dehydration:

Risk factors:

  • Elderly patients
  • Concurrent diuretic use
  • Conditions causing fluid loss (vomiting, diarrhea)

Signs to watch for:

  • Dizziness, lightheadedness upon standing
  • Fainting
  • Rapid heartbeat

Management:

  • Rise slowly from sitting/lying positions.
  • Ensure adequate fluid intake.
  • Discuss diuretic adjustments with your doctor.

5. Genital Mycotic (Yeast) Infections

Jardiance increases sugar in the urinary tract, fueling fungal growth.

Features:

  • Itching, redness, swelling around the genital area
  • White or yellowish discharge

Treatment:

  • Over-the-counter antifungal creams or prescription therapy.
  • Good hygiene and keeping the area dry can help prevent recurrence.

6. Fournier’s Gangrene

A very rare but life-threatening necrotizing fasciitis of the genital/perineal region.

Red flags:

  • Severe pain, tenderness, swelling in genital area
  • Fever, malaise
  • Skin discoloration or ulcers

Urgent steps:

  • This condition requires immediate surgical and antibiotic intervention.
  • Call 911 or go to the nearest emergency department if suspected.

7. Bone Fractures and Amputation Risk

Some SGLT2 inhibitors have been associated with reduced bone mineral density and increased fracture risk. Though less clear for Jardiance specifically, caution is advised in patients with:

  • Osteoporosis
  • History of fractures

Additionally, there has been debate over a possible heightened risk of lower-limb amputations (primarily seen with canagliflozin, a related drug). While Jardiance’s direct link remains unconfirmed, it’s wise to:

  • Inspect feet daily for cuts, blisters, redness
  • Maintain good foot hygiene
  • Report any non-healing sores promptly

8. Hypoglycemia (Low Blood Sugar)

Jardiance alone rarely causes hypoglycemia. However, when combined with insulin or sulfonylureas, the risk increases.

Symptoms:

  • Shakiness, sweating
  • Irritability, confusion
  • Rapid heartbeat, hunger
  • Seizures or loss of consciousness in severe cases

Prevention:

  • Monitor blood sugar regularly.
  • Discuss dose adjustments with your healthcare team.

9. Severe Skin Reactions

Extremely rare but serious dermatologic events can occur, including:

  • Drug Reaction with Eosinophilia and Systemic Symptoms (DRESS)
  • Stevens–Johnson syndrome

Watch for:

  • Widespread rash, blistering
  • Fever, swollen lymph nodes
  • Facial swelling, organ involvement

Action:

  • Discontinue Jardiance immediately and seek emergency care if a severe rash develops.

Monitoring and Risk Reduction

To lower your chances of experiencing the worst side effects:

  • Maintain appropriate hydration, especially during illness or hot weather.
  • Have routine labs to check kidney function, electrolytes, and blood counts.
  • Perform daily foot and genital inspections.
  • Use blood pressure and blood glucose logs to spot concerning trends.
  • Report any new or worsening symptoms to your healthcare provider without delay.

When to Seek Medical Help

Certain red-flag symptoms demand prompt evaluation:

  • Signs of DKA: nausea, vomiting, abdominal pain, rapid breathing
  • High fever or signs of systemic infection with urinary symptoms
  • Sudden decrease in urine output or swelling in extremities
  • Severe dizziness, fainting, or rapid heartbeat
  • Intense genital/perineal pain, redness, or swelling
  • Easy bruising, bleeding, or unexplained rash

If you’re ever uncertain, consider a free, online symptom check, using the doctor approved Ubie Symptom Checker or call your doctor right away.

Talk to Your Doctor

This overview covers the worst side effects of Jardiance but doesn’t replace personalized medical advice. Always discuss any new or concerning symptoms with your healthcare provider. If you experience life-threatening signs—such as chest pain, severe shortness of breath, or altered consciousness—call 911 or go to the nearest emergency department.


Sources: U.S. Food and Drug Administration (FDA) Prescribing Information; Peer-reviewed clinical trials and professional diabetes guidelines.

(References)

  • * DeFronzo RA, Lewin A, Patel S, Liu D, Kaste R, Woerle HJ, Broedl UC. Combination of empagliflozin and linagliptin as second-line therapy in subjects with type 2 diabetes inadequately controlled on metformin. Diabetes Care. 2015 Mar;38(3):384-93. doi: 10.2337/dc14-2364. Epub 2015 Jan 12. PMID: 25583754.

  • * Zinman B, Wanner C, Lachin JM, Fitchett D, Bluhmki E, Hantel S, Mattheus M, Devins T, Johansen OE, Woerle HJ, Broedl UC, Inzucchi SE, EMPA-REG OUTCOME Investigators. Empagliflozin, Cardiovascular Outcomes, and Mortality in Type 2 Diabetes. N Engl J Med. 2015 Nov 26;373(22):2117-28. doi: 10.1056/NEJMoa1504720. Epub 2015 Sep 17. PMID: 26378978.

  • * Voors AA, Angermann CE, Teerlink JR, Collins SP, Kosiborod M, Biegus J, Ferreira JP, Nassif ME, Psotka MA, Tromp J, Borleffs CJW, Ma C, Comin-Colet J, Fu M, Janssens SP, Kiss RG, Mentz RJ, Sakata Y, Schirmer H, Schou M, Schulze PC, Spinarova L, Volterrani M, Wranicz JK, Zeymer U, Zieroth S, Brueckmann M, Blatchford JP, Salsali A, Ponikowski P. The SGLT2 inhibitor empagliflozin in patients hospitalized for acute heart failure: a multinational randomized trial. Nat Med. 2022 Mar;28(3):568-574. doi: 10.1038/s41591-021-01659-1. Epub 2022 Feb 28. PMID: 35228754; PMCID: PMC8938265.

  • * The EMPA-KIDNEY Collaborative Group, Herrington WG, Staplin N, Wanner C, Green JB, Hauske SJ, Emberson JR, Preiss D, Judge P, Mayne KJ, Ng SYA, Sammons E, Zhu D, Hill M, Stevens W, Wallendszus K, Brenner S, Cheung AK, Liu ZH, Li J, Hooi LS, Liu W, Kadowaki T, Nangaku M, Levin A, Cherney D, Maggioni AP, Pontremoli R, Deo R, Goto S, Rossello X, Tuttle KR, Steubl D, Petrini M, Massey D, Eilbracht J, Brueckmann M, Landray MJ, Baigent C, Haynes R. Empagliflozin in Patients with Chronic Kidney Disease. N Engl J Med. 2023 Jan 12;388(2):117-127. doi: 10.1056/NEJMoa2204233. Epub 2022 Nov 4. PMID: 36331190; PMCID: PMC7614055.

  • * RECOVERY Collaborative Group. Empagliflozin in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial. Lancet Diabetes Endocrinol. 2023 Dec;11(12):905-914. doi: 10.1016/S2213-8587(23)00253-X. Epub 2023 Oct 18. PMID: 37865101; PMCID: PMC10957483.

  • * Butler J, Jones WS, Udell JA, Anker SD, Petrie MC, Harrington J, Mattheus M, Zwiener I, Amir O, Bahit MC, Bauersachs J, Bayes-Genis A, Chen Y, Chopra VK, Figtree G, Ge J, Goodman SG, Gotcheva N, Goto S, Gasior T, Jamal W, Januzzi JL, Jeong MH, Lopatin Y, Lopes RD, Merkely B, Parikh PB, Parkhomenko A, Ponikowski P, Rossello X, Schou M, Simic D, Steg PG, Szachniewicz J, van der Meer P, Vinereanu D, Zieroth S, Brueckmann M, Sumin M, Bhatt DL, Hernandez AF. Empagliflozin after Acute Myocardial Infarction. N Engl J Med. 2024 Apr 25;390(16):1455-1466. doi: 10.1056/NEJMoa2314051. Epub 2024 Apr 6. PMID: 38587237.

  • * Modzelewski KL, Pipilas A, Bosch NA. Comparative Outcomes of Empagliflozin to Dapagliflozin in Patients With Heart Failure. JAMA Netw Open. 2024 May 1;7(5):e249305. doi: 10.1001/jamanetworkopen.2024.9305. Epub 2024 May 1. PMID: 38696170; PMCID: PMC11066699.

  • * Wanner C, Iliev H, Duarte N, Schueler E, Soares AR, Thanam V, Pfarr E. Safety of Empagliflozin: An Individual Participant-Level Data Meta-Analysis from Four Large Trials. Adv Ther. 2024 Jul;41(7):2826-2844. doi: 10.1007/s12325-024-02879-w. Epub 2024 May 21. PMID: 38771475; PMCID: PMC11213770.

  • * Khan S, Broce A. Empagliflozin-induced Myopathy. JCEM Case Rep. 2024 Dec;2(12):luae216. doi: 10.1210/jcemcr/luae216. Epub 2024 Nov 28. PMID: 39611184; PMCID: PMC11604052.

  • * Agarwal R, Green JB, Heerspink HJL, Mann JFE, McGill JB, Mottl AK, Rosenstock J, Rossing P, Vaduganathan M, Brinker M, Edfors R, Li N, Scheerer MF, Scott C, Nangaku M, CONFIDENCE Investigators. Finerenone with Empagliflozin in Chronic Kidney Disease and Type 2 Diabetes. N Engl J Med. 2025 Aug 7;393(6):533-543. doi: 10.1056/NEJMoa2410659. Epub 2025 Jun 5. PMID: 40470996.

Thinking about asking ChatGPT?Ask me instead

Tell your friends about us.

We would love to help them too.

smily Shiba-inu looking

For First Time Users

What is Ubie’s Doctor’s Note?

We provide a database of explanations from real doctors on a range of medical topics. Get started by exploring our library of questions and topics you want to learn more about.

Was this page helpful?

Purpose and positioning of servicesUbie Doctor's Note is a service for informational purposes. The provision of information by physicians, medical professionals, etc. is not a medical treatment. If medical treatment is required, please consult your doctor or medical institution. We strive to provide reliable and accurate information, but we do not guarantee the completeness of the content. If you find any errors in the information, please contact us.